MYOCIT - Baricitinib in the treatment of new-onset juvenile dermatomyositis: a phase II trial
The MYOCIT study is a Phase II clinical trial investigating a medication named baricitinib for children and young people recently diagnosed with juvenile dermatomyositis (JDM). JDM is a rare condition that causes muscle weakness and skin rashes. In this study, researchers want to see if baricitinib helps improve symptoms of JDM. They will be looking for at least a 20% improvement in several key areas, such as muscle strength, how well the person can move, and the appearance of skin rashes, without major worsening in other areas. This trial aims to understand the treatment's effectiveness and safety in a structured way. The goal is to find better ways to manage JDM for those affected.
At a glance
What is this study about?
Imagine you have a condition called juvenile dermatomyositis (JDM), which affects your muscles and skin. Doctors are always looking for better ways to help young people with JDM. That's where clinical trials like MYOCIT come in. This particular study is looking into a medicine called baricitinib. It's a 'Phase II' trial, which means it’s one of the first careful steps to see if a new treatment is effective and safe for a specific condition in people, after initial safety tests.
The main aim of this study is to see if baricitinib helps improve the symptoms of JDM. The researchers will be carefully checking if there's at least a 20% improvement in important signs of the condition, like how well the muscles are working, the extent of skin rashes, and overall physical activity. They want to see these improvements in at least three out of six key areas, without any of the other areas getting significantly worse. This helps them understand if the medicine is making a meaningful difference for the young people taking part.
Beyond simply looking for overall improvement, the study will also track other details at different points in time. This includes checking for even higher levels of improvement (like 50%, 70%, or 90%), how much other scores related to JDM change, and if the disease becomes inactive. They will also keep a close eye on any side effects, how the body handles the medicine, and even changes in certain cells in the blood and muscle tissue. All this information helps researchers build a full picture of how baricitinib might work for young people with JDM.
Key takeaways
- The MYOCIT study is for young people with a new diagnosis of juvenile dermatomyositis.
- It's a Phase II trial testing a medicine called baricitinib.
- Researchers will check for at least a 20% improvement in key symptoms.
- Participation involves regular visits and assessments over several months.
- This study aims to find better treatments for juvenile dermatomyositis.
Who may be eligible?
To join the MYOCIT study, participants need to be 18 years old or older. This study is open to both male and female individuals.
The trial is specifically for people who have been newly diagnosed with juvenile dermatomyositis.
Further checks by the study team will ensure that participants meet all the detailed criteria to safely take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or over?
- Have you recently been diagnosed with juvenile dermatomyositis?
- Are you able to attend regular appointments for checks and tests?
- Are you comfortable with the possibility of blood tests and other medical assessments?
What does participation involve?
If you decide to take part in this study, you would receive the study medication, baricitinib. Researchers would monitor your health and how the medication affects your juvenile dermatomyositis over several weeks, especially at weeks 4, 8, 12, 16, and 24. They will regularly check your symptoms, such as muscle strength, skin rashes, and how active the disease is, using specific scoring systems.
Throughout the study, you might have various assessments, which could include blood tests to measure certain chemicals in your body and to see how the medication is being processed. If you have lung problems related to your condition, they might also check your lung function. In some cases, there might be repeat muscle biopsies, which involve taking a small sample of muscle tissue to examine under a microscope, following international guidelines. The total duration of the study participation for each individual will involve follow-up appointments up to week 24.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is juvenile dermatomyositis?
It's a rare condition that causes muscle weakness and skin rashes in children and young people.
What is baricitinib?
Baricitinib is a medicine being tested in this study to see if it can help improve symptoms of juvenile dermatomyositis.
What does 'Phase II trial' mean?
It means this is an early stage of testing, where doctors are looking to see how well the medicine works and if it's safe for people with the condition.
How will they know if the treatment is working?
Doctors will measure improvements in your symptoms, like muscle strength and skin rashes, looking for at least a 20% improvement in several key areas.
Will I have to have many tests?
The study involves regular check-ups, blood tests, and other assessments to monitor your health and how the treatment is working.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.